Press Release

PRINCETON, N.J., March 30, 2022 /PRNewswire/ — EDDA Technology, a global leading provider in advanced imaging-guided precision treatment solutions, announced today it has entered into an agreement with the Society of Interventional Oncology (SIO) for their ACCLAIM Trial (Ablation with Confirmation of Colorectal Liver Metastases Prospective Trial for Microwave Ablation as a Local Cure). IQQA®-BodyImaging Interventional will be used to provide 3D assessment of the ablation zone and margin for selected colorectal liver metastases.

In this prospective, multi-center, international trial, SIO proposes to establish microwave ablation (MWA) as the preferred treatment option for selected colorectal liver metastases that can be ablated with sufficient margins. The study will be the first global, prospective trial to use an objective and reproducible technical outcome in its study design, which SIO believes will drive important changes to future treatment guidelines. The ACCLAIM study will estimate disease-free survival of colorectal liver metastases treated with MWA incorporating 3D ablation software (EDDA Technology) margin confirmation intraoperatively and through a subsequent independent review centralized validation process.

The IQQA® platform provides comprehensive 3D image analysis using MR and CT, and has been used in over 80,000 cases worldwide for surgery and treatment with substantial time-saving. This exceptionally intuitive solution supports in-depth quantitative volumetry with fast, dependable results and allows for versatility of transplantation, resection, or interventional procedure planning.

“IQQA® is a proven innovation to support physicians in providing individualized and optimized treatment solution. Powered by our precision 3D capabilities, IQQA® aims to facilitate the next generation of precision surgery and treatment.”, said Dr. Jianzhong Qian, President and CEO of EDDA Technology. “We’re glad that the IQQA platform was chosen by SIO for this global trial which will bring important clinical information for the future interventional treatment guidelines.”

About The Society of Interventional Oncology (SIO)

The Society of Interventional Oncology (SIO) is a non-profit association that supports and promotes the field of interventional oncology (IO). SIO provides a community for IO professionals to connect and work together to advance IO as the fourth pillar of cancer therapy worldwide alongside medical, surgical and radiation oncology. SIO offers a space for IO practitioners to continue their professional development, access advocacy and research, and engage in idea-sharing with peers. SIO was established in January of 2017 by the Board of Directors of the former conference WCIO, now known as SIO’s Annual Scientific Meeting. www.sio-central.org

About EDDA Technology

EDDA Technology is an innovative leader in the rapidly growing field of intelligent robotic solutions for precision surgery. Pioneering a “fully quantitative, interactive” approach to intelligent imaging analytics and robotic integration, the company has built a proprietary technology platform to facilitate pre-surgical planning and simulation, intra-operative navigation, post-operative evaluation. With its end-to-end enabling platform, EDDA’s goal is to form a comprehensive ecosystem of clinical practice, connection and education to support physicians and patient management in all tiers of hospitals. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com

SHANGHAI and SUZHOU, China, April 7, 2021 /PRNewswire/ — EDDA Healthcare and Technology Holding Ltd. and its subsidiaries EDDA Technology (Shanghai) Ltd., EDDA Technology Medical Solutions (Suzhou) Ltd., and EDDA Technology, Inc (Princeton, NJ, USA), (hereafter jointly referred to as EDDA Technology), a pioneer in the rapidly growing field of intelligent robotic solutions for precision surgery, today announced the completion of a US$150 million financing round. Softbank Vision Fund 2* led this investment round with participation from OrbiMed and 3W Fund. The company’s existing investors include Morningside Ventures, Matrix Partners China, SBCVC, BOCGI, Trust Bridge, and Draper Dragon etc.

EDDA Technology brings innovative precision 3D medical imaging solutions to support physicians and enable improved workflow and patient care in robotic surgery. The company’s end-to-end enabling IQQA® platform supports pre-surgical planning and simulation, intra-operative navigation, and post-operative evaluation. The IQQA® products and services have been commercially adopted in hundreds of hospital departments, including Mayo Clinic in the US, and Peking Union Medical College Hospital, West China Hospital, and Shanghai Ruijin Hospital in China.

In 2020, China NMPA granted Category III registration certificate for IQQA®-Guide as the country’s first surgical navigation medical device for soft tissue organs, with a statement describing it as having “significant clinical benefits, increasing interventional accuracy, reducing the number of needle passes and intraoperative CT scanning”. The product was also cleared by the US FDA.

Dr. Jianzhong Qian, President and CEO of EDDA Technology, Fellow of American Institute for Medical and Biological Engineering (AIMBE), stated: “Modern surgery has entered a new precision era. EDDA Technology’s solution integrates intelligent medical imaging analytics with robots for precision surgery, and overcomes the problems of lack of intelligent planning and limited image guidance in traditional robot-assisted surgeries. This round of investment from Softbank Vision Fund 2, OrbiMed and 3W with their vision and market insight, will further accelerate the company’s strategic growth, and further support the company to continuously lead technological innovation in precision surgery, capture the untapped market of intelligent surgical robots including hospitals in second- and third-tier cities, and utilize technologies to facilitate the diagnosis and treatment of major diseases such as cancer.”

“We believe EDDA Technology is an innovative health tech leader who is combining precision surgery with AI and robotics to provide better clinical care,” said Joanne Xu, Partner at SoftBank Investment Advisers. “We look forward to partnering with Dr. Jianzhong Qian and the EDDA team to support their mission of using advanced technologies to improve patient outcomes in China and across the globe.”

Ms. Iris Wang, Partner of OrbiMed, stated, “EDDA Technology’s intelligent robotic surgical products provide personalized solutions for precision surgery which dramatically improved the accuracy and reduced risks of surgeries. We are very confident in a successful commercialization of EDDA’s products led by its visionary management team. We look forward to EDDA’s further achievement in advancing AI-empowered precision surgical treatments to address the unmet medical needs and benefit more patients around the world.”

Ms. Cathy Chen, Managing Director of 3W Fund, expressed, “as a pioneer in robotic treatment and precision surgery solutions, EDDA Technology has a track record of delivering to doctors a full range of integrated services covering early detection, diagnosis and treatment planning. We trust that the EDDA team led by Dr. Jianzhong Qian will continue to leverage its technological edge and rich clinical deployment experience for commercializing its products and empower healthcare industries with medical AI.”

*As of the date of this press release, SoftBank Group Corp. has made capital contributions to allow investments by SoftBank Vision Fund 2 (“SVF 2”) in certain portfolio companies. The information included herein is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy limited partnership interests in any fund, including SVF 2. SVF 2 has yet to have an external close, and any potential third-party investors shall receive additional information related to any SVF 2 investments prior to closing.

About EDDA Technology

EDDA Technology is an innovative leader in the rapidly growing field of intelligent robotic solutions for precision surgery. Pioneering a “fully quantitative, real-time interactive” approach to intelligent imaging analytics and robotic integration, the company has built a proprietary technology platform to facilitate pre-surgical planning and simulation, intra-operative navigation, post-operative evaluation. With its end-to-end enabling platform, EDDA’s goal is to form a comprehensive ecosystem of clinical practice, connection and education to support physicians and patient management in all tiers of hospitals. EDDA Technology has received multiple registrations and clearances from the NMPA in China and the FDA in the United States. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com

About Softbank Vision Fund

The SoftBank Vision Fund seeks to accelerate the AI revolution through investments in market-leading, tech-enabled growth companies across consumer, enterprise software, fintech, frontier tech, health tech, real estate, transportation and logistics, and education. To date, SoftBank Vision Fund 1 and Vision Fund 2 have made a combined 21 investments in China.

About OrbiMed

OrbiMed is a leading global healthcare investment firm, with $18 billion in assets under management across a range of private equity funds, public equity funds, and private credit/royalty funds. The company has been investing globally for over 30 years across the healthcare industry from early-stage private companies to large multinational corporations. Its team has over 100 scientific, medical, investment and other professionals located in New York, Hong Kong, Shanghai, San Francisco, Mumbai, Herzliya, etc.

About 3W Fund

3W Fund is an investment management firm based in Hong Kong with expertise in equity investments. Adopting fundamental research methodology, the firm invests in both private and public markets, with primary focuses on consumer, TMT and healthcare sectors. 3W Fund intends to generate capital appreciation with continuous efforts in company research and long-term investment horizon. As a firm, 3W Fund honors integrity, intellectual curiosity and independent thinking.

PRINCETON, N.J., October 8, 2018 /PRNewswire/ — EDDA Technology, a global leading provider in advanced imaging-guided precision treatment solutions, announced today that the company has completed the installation of IQQA ® – Liver MultiModality at Mayo Clinic in Jacksonville, Florida.

The IQQA ® platform is now incorporated in all three Mayo Clinic main campuses (Minnesota, Arizona, and Florida) as part of the continued innovation in medical technology for Mayo patients. The IQQA ® platform provides comprehensive 3D image analysis using MR and CT, and has been used in over 45,000 cases worldwide for surgery and treatment with substantial time- saving. This exceptionally intuitive solution supports in-depth quantitative volumetry with fast, dependable results and allows for versatility of transplantation, resection, or interventional procedure planning.

Mayo Clinic is the largest integrated transplant provider in the United States. Multidisciplinary team (MDT) including experts in surgery, radiology, and transplant work together to provide care for cancer patients and living donors. “IQQA ® is a proven innovation to support MDT physicians in providing individualized and optimized treatment solution”, said Dr. Jianzhong Qian, President and CEO of EDDA Technology. “Powered by our precision 3D capabilities, IQQA ® aims to facilitate the next generation of precision surgery and treatment.”

About EDDA Technology

EDDA Technology, Inc. is an innovative clinical solution provider in the rapidly growing field of imaging-guided minimally invasive and robotic treatment. Pioneering a “fully quantitative, real- time interactive” approach to multimodality imaging analysis and guidance, EDDA offers a series of next generation computer-assisted solutions for the entire patient management cycle, by enabling early detection and diagnosis, and enhancing efficiency and precision in treatment planning, guidance, monitoring, and follow-up. EDDA's goal is to deliver, with broad accessibility, advanced imaging analytics technology and services that improve clinical workflow and accuracy. EDDA is headquartered in Princeton, New Jersey, and has subsidiaries in Shanghai and Suzhou, China. IQQA ® is a registered trademark of EDDA Technology. www.eddatech.com

Frost & Sullivan Applauds EDDA’s IQQA® Platform, an Advanced
Imaging Analytics Technology that Improves Clinical Workflow and Accuracy

IQQA®’s exceptional ease of use and clinical versatility enhance efficiency and precision in treatment planning, guidance, monitoring, assessment and follow-up

MOUNTAIN VIEW, Calif. — March 22, 2016 — Based on its recent analysis of the medical imaging analytics market, Frost & Sullivan recognizes EDDA Technology, Inc. (EDDA) with the 2016 North America Frost & Sullivan Award for Product Leadership. EDDA supports a patient-specific and multi-disciplinary approach to cancer treatment with its innovative IQQA® platform and product suite. IQQA® adopts the proprietary “fully quantitative, real-time interactive” approach to multimodality imaging analytics. Uniquely, it is a comprehensive solution that covers the entire patient management cycle, including pre-operative planning, intra-operative navigation and monitoring, as well as post-operative assessment for cancer treatment.

The IQQA® platform and product suite was developed to optimally use multimodality imaging and coordinate the workflow of multiple stakeholders along the continuum of care, including radiologists, interventional radiologists, surgeons and oncologists. IQQA®-BodyImaging, provides powerful precision 3D imaging analytics features for treatment planning and assessment to support open surgery, interventional procedures, minimally invasive and robotic surgery. IQQA®-Guide supports intra-operative precision 3D navigation. The IQQA® product suite has been cleared by the Food and Drug Administration (FDA). It is the most complete workflow solution for thoracic, abdominal, and pelvic cancer treatment.

Through its proprietary IQQA® Web-enabling technology and clinical partnership, EDDA offers cloud-based OnDemand services that can employ IQQA® applications for treatment planning and assessment—anytime, anywhere, through a real-time interactive interface. Physicians may thus participate from different locations to collaboratively determine optimal surgical plans, and the resulting treatment plan can be immediately employed into procedures inside local operating room.

“EDDA Technology, through its IQQA® Enabling Imaging Platform, provides quantitative, real-time, interactive and personalized precision treatment solutions,” said Frost & Sullivan Research Analyst Swathi Allada. “In the rapidly growing field of minimally invasive and robotic surgeries, where multimodality imaging is gaining traction, EDDA’s pioneering approach and product offerings are of great significance in ushering in the next generation of treatments.”

“Owing to its clinical depth and breadth, EDDA’s Product Suite aligns perfectly with the US healthcare system’s movement toward more IT workflow-based integration,” noted Allada. “EDDA’s technology is designed to fit within the existing surgical workflow. An important significance of IQQA® Imaging Platform is that it applies across multiple surgical procedures. With exceptional ease of use and clinical versatility, it facilitates efficiency and precision in treatment planning, guidance, monitoring, and follow-up, thus drastically improving the current standard of care. Its streamlined and real-time interactive processes that reduce the time of planning, treatment and assessment, while increasing overall clinical quality, have earned the IQQA® platform the prestigious 2016 North America Frost & Sullivan Award for Product Leadership.

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality, gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

 

About EDDA Technology, Inc. (EDDA)

EDDA Technology, Inc. is an innovative clinical solution provider in the rapidly growing field of imaging-guided minimally invasive and robotic treatment. Pioneering a “fully quantitative, real-time interactive” approach to multimodality imaging analysis and guidance, EDDA offers a series of next generation computer-assisted solutions for the entire patient management cycle, by enabling early detection and diagnosis, and enhancing efficiency and precision in treatment planning, guidance, monitoring, and follow-up. EDDA’s goal is to deliver, with broad accessibility, advanced imaging analytics technology and services that improve clinical workflow and accuracy. EDDA is headquartered in Princeton, New Jersey, and has subsidiaries in Shanghai and Suzhou, China. IQQA® is a registered trademark of EDDA Technology.  www.eddatech.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

PRINCETON, NJ, November 25, 2015

EDDA Technology, a global leading provider in advanced imaging-guided precision treatment solutions, announced today that the company has received FDA clearance on IQQA®-Guide, a system that supports intra-operative precision 3D navigation for surgical procedures of thoracic, abdominal, and pelvic soft-organs.

IQQA®-Guide is the latest addition to the IQQA® Platform and Product Suite.  It expands the award-winning IQQA® precision 3D imaging analytics into the operating room.  Fully quantified and patient-specific IQQA® anatomic models are extracted from multi-modality images, and utilized for on-the-fly 3D navigation to support physicians in “seeing through” organ surfaces and quantitatively referencing anatomies of interest in 3D during surgery. Clinical studies (WICO 2015) suggest that IQQA®-Guide may help reduce the use of intra-operative CT scans during imaging-guided surgical procedures.

The treatment planning and follow-up assessment features provided by IQQA® -BodyImaging, a part of the IQQA® Platform, have already been widely used for liver, kidney, and lung cancers. IQQA® -BodyImaging has been proven to provide significant time-saving and improved patient care in more than 22,000 cases.

“With the latest FDA clearance, the IQQA® Platform now covers pre-operative planning, intra-operative navigation and monitoring, and post-operative assessment to complete the full cycle of imaging-guided precision treatment,” said Dr. Jianzhong Qian, President and CEO of EDDA Technology. “Powered by our precision 3D capabilities, IQQA®-Guide may help facilitate the next generation of minimally invasive and robotic treatments in precision medicine.”

EDDA will exhibit its IQQA® Platform and Product Suite as well as cloud-based service in Booth #8127 at RSNA 2015.

IQQA®-Guide, intra-operative precision 3D navigation system,
for imaging-guided surgical procedures of thoracic, abdominal,and pelvic organs

About EDDA Technology

EDDA Technology, Inc. is an innovative clinical solution provider in the rapidly growing field of imaging-guided minimally invasive and robotic treatment. Pioneering a “fully quantitative, real-time interactive” approach to multimodality imaging analysis and guidance, EDDA offers a series of next generation computer-assisted solutions for the entire patient management cycle, by enabling early detection and diagnosis, and enhancing efficiency and precision in treatment planning, guidance, monitoring, and follow-up. EDDA’s goal is to deliver, with broad accessibility, advanced imaging analytics technology and services that improve clinical workflow and accuracy. EDDA is headquartered in Princeton, New Jersey, and has subsidiaries in Shanghai and Suzhou, China. IQQA® is a registered trademark of EDDA Technology.  www.eddatech.com

PRINCETON, NJ, January 12, 2015

EDDA Technology, a global leading provider in computer-assisted radiology and surgery solutions, announced that the company will be exhibiting at Arab Health 2015 in Dubai, United Arab Emirates. The company will showcase its award-winning IQQA® Platform and Product Suite, an innovative technology platform in imaging-guided cancer treatment.

The IQQA® Platform and Product Suite provides real-time, quantitative multimodality imaging solutions to support the entire patient management cycle, including early detection, treatment planning, intra-operative guidance and monitoring, and post-operative follow-up. IQQA® is currently being used by leading cancer centers worldwide, including King Faisal Specialist Hospital & Research Centre (KSA), Mayo Clinic (USA), Massachusetts General Hospital (USA), University of California San Francisco Medical Center (USA), University of Colorado Hospital (USA), as well as many other global luminary sites.

The company ‘s key highlight will be IQQA®-BodyImaging, which extends the proprietary fast and powerful 3D features  in the IQQA® product portfolio to thoracic, abdominal and pelvic scans. Features such as virtual knife for surgery and virtual needle for interventional planning, monitoring and follow-up, provide comprehensive tools for precision treatment delivery and quantifiable patient assessment.

“We are excited to bring to Arab Health our IQQA® Platform and Product Suite, an offering that covers close to 50% of the world’s cancer incidences and also addresses key challenges related to the treatment of prevalent lung and liver cancers in the region,” said Dr. Jianzhong Qian, president and CEO of EDDA Technology, and fellow of the American Institute of Medical and Biological Engineering (AIMBE). “We are confident that the IQQA® innovative solutions will aid in meeting and exceeding the clinical needs and treatment challenges in the Arab health market and abroad.”

As part of IQQA® Product Suite, the company will also be demonstrating IQQA®-Liver Multimodality and IQQA®-Chest. IQQA®-Liver Multimodality has been proven to offer significant time-saving and improved patient care for liver cancer treatment in more than 15,000 cases worldwide since 2009. IQQA®-Chest has been shown in a prospective study to assist physicians with early detection, by increasing physicians’ detection sensitivity of small lung nodules on X-ray from 63.8% to 92.7% (Academic Radiology Journal 2008;15:571-575).

EDDA will be exhibiting in Booth Z4E27 in the US Pavilion at Arab Health 2015.

IQQA® for thoracic, abdominal,and pelvic applications in cancer treatment planning, monitoring and follow-up.

About EDDA Technology

EDDA Technology, Inc. is an innovative clinical solution provider in the rapidly growing field of imaging-guided cancer treatment. By adopting a “fully quantitative, real-time interactive” approach to multimodality imaging analysis and guidance,  EDDA offers a series of next generation computer-assisted solutions to the entire patient management cycle, including enabling early detection and diagnosis, and enhancing efficiency and precision in treatment planning, guidance, monitoring, and follow-up. EDDA’s goal is to deliver, with broad accessibility, advanced imaging analytics technologies and services that improve clinical workflow and accuracy. EDDA is headquartered in Princeton, New Jersey, USA and has subsidiaries in China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com

PRINCETON, NJ, November 21, 2014

EDDA Technology, a global leading provider in advanced real-time interactive quantitative imaging solutions, announced today that the company has received FDA clearance on IQQA®-BodyImaging. The new product will be introduced as the latest addition to the IQQA® Platform and Product Suite for imaging-guided cancer treatment at the 100th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, IL later this month. Also being introduced at the RSNA is the company’s cloud-based OnDemand service with its clinical collaborator Massachusetts General Hospital.

The IQQA® Platform and Product Suite was developed with a specific aim to maximize the utilization of multimodality imaging and its benefit for multiple stakeholders along the cycle of patient care, which include radiologists, interventional radiologists, surgeons, and oncologists.  By supporting efficient collaboration for optimal workflow and treatment management with clinical depth and OnDemand accessibility, the IQQA® Platform enables a patient-specific, disease-targeted, and multidisciplinary approach to cancer treatment.

The newly FDA cleared  IQQA®-BodyImaging extends the award-winning fast and powerful 3D features found in the IQQA® product portfolio to thoracic, abdominal and pelvic multimodality scans. Features such as virtual knife for surgery and virtual needle for interventional procedural planning, monitoring and follow-up, provide comprehensive tools for tumor board assessment.

“We are pleased to announce the launch of IQQA®-BodyImaging, which significantly broadens our product and service offering to cover close to 50% of the world’s cancer incidences,” said Dr. Jianzhong Qian, president and CEO of EDDA Technology, “Our team at EDDA is committed to innovation to support the latest treatment options, including minimally invasive and robotic-assisted approaches, where information from imaging is essential for optimal treatment planning, guidance and confirmation.”

The company will also be demonstrating IQQA®-Liver Multimodality, as part of the IQQA® Product Suite. IQQA®-Liver Multimodality is currently being used by physicians worldwide for real-time, interactive treatment planning and post-procedural assessment of liver diseases. IQQA®-Liver Multimodality has been proven to provide significant time-saving and improved patient care in more than 15,000 cases since 2009.

Through its proprietary IQQA® web-enabling technology and clinical partnership, EDDA offers OnDemand services for practices to use IQQA applications anytime and anywhere. “Through a combination of technology and in-depth clinical expertise, the MGH 3D Imaging Service offers access to our team of dedicated 3D technologists to other hospitals and imaging centers with the goal of improving patient care by enhancing the efficiency, reliability, and scalability of 3D imaging solutions for clinical decision support,” said Dr. Gordon J. Harris, director of the 3D Imaging Service at Massachusetts General Hospital.

The IQQA® Product Suite also includes IQQA®-Guide (work-in-progress) for intraoperative 3D navigation, IQQA®-LiverFunction (work-in-progress) for localized hepatic functional analysis using 3D SPECT, and IQQA®-Chest CAD for small lung nodule detection. EDDA will exhibit its IQQA® Platform and Product Suite in Booth #4571 at RSNA 2014.

IQQA®-BodyImaging for thoracic, abdominal,and pelvic applications of
cancer treatment planning, monitoring and follow-up.

About EDDA Technology

EDDA Technology, Inc. is an innovative clinical solution provider in the rapidly growing field of imaging-guided cancer treatment. By adopting a “fully quantitative, real-time interactive” approach to multimodality imaging analysis and guidance,  EDDA offers a series of next generation computer-assisted solutions to the entire patient management cycle, including enabling early detection and diagnosis, and enhancing efficiency and precision in treatment planning, guidance, monitoring, and follow-up. EDDA’s goal is to deliver, with broad accessibility, advanced imaging analytics technologies and services that improve clinical workflow and accuracy. EDDA is headquartered in Princeton, New Jersey, and has subsidiaries in Shanghai and Suzhou, China. IQQA® is a registered trademark of EDDA Technology.

By Editorial staff writers

EDDA Technology previewed its IQQA-Guide as a work-in-progress at the annual meeting of the Radiological Society of North America (RSNA) in Chicago.

The IQQA-Guide seeks to bring interactive quantitative technology into the operating room by offering 3D image guidance for abdominal and thoracic biopsy, interventional procedures and surgery, according to the Princeton, N.J.-based company. IQQA-Guide utilizes a 3D map of anatomic representations extracted from multimodality image datasets. Through registration algorithms and electromagnetic tracking, it provides tracking and referencing to anatomic features of interest in 3D.

By AuntMinnie.com staff writers

Computer-aided detection (CAD) software developer EDDA Technology will feature enhancements developed for its IQQA quantitative interventional image guidance and work flow software at the 2012 RSNA meeting in Chicago.

The company will discuss the potential of IQQA-Guide. The work-in-progress product provides real-time 3D image guidance in the interventional suite for abdominal and thoracic biopsy, interventional procedures, and surgery. IQQA-Guide utilizes a 3D map of individualized anatomic representations from multimodality images, providing real-time tracking and referencing to anatomic features of interest in 3D.

EDDA will also showcase IQQA-Liver, an organ-specific version of the software that has been applied more than 4,000 cases worldwide since introduction in 2009, according to the company. It features real-time measurement of the spatial relationships between tumors, organs, vessel, and duct to aid needle or catheter navigation.

IQQA-Liver Function, IQQA-Chest Enterprise CAD, and two works-in-progress, IQQA-BodyImaging and IQQA-TomoS CAD for digital x-ray tomosynthesis, also will be shown at the conference

PRINCETON, NJ, November 21, 2012

EDDA Technology announced today that the company will demonstrate the generalization of its proven technologies of Real-time Interactive Fully 3D Quantitative Imaging in an enhanced IQQA Platform at the 98th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA).

The enhanced IQQA Platform answers to the challenge of maximizing the potential of imaging in
coordinating an optimal workflow involving multiple stakeholders along the cycle of patient care,
including radiologists, interventional radiologists, surgeons, and oncologists. The decision support
provided by IQQA covers the full range of disease-centralized patient management in the
abdominal and thoracic areas, from detection, diagnosis, pre-treatment planning, to intraoperative
navigation, and post-treatment follow up.

A market-proven product of the platform, IQQA®-Liver for 3D real-time quantitative planning and
assessment, is currently used by radiologists and surgeons worldwide in liver surgery,
transplantation, and interventional centers. Substantial time saving and improved care was
demonstrated in over 4,000 cases using IQQA-Liver in hospitals since the first commercial
system installation in Q2 2009.

Real-time interactive applications with fully 3D capabilities are the prerequisite of strong clinical
decision support from imaging. The same proprietary technology behind IQQA®-Liver has now
been extended to other organs in thoracic and abdominal application areas; to offer physicians
real-time quantitative decision support that goes well beyond the 3D visualization domain. It
enables physicians to utilize the quantitative information of the organ, lesion, vessels, and ducts,
as well as the quantified spatial relations among these anatomies of interests, to make their own
individualized decision based upon own knowledge and experience in a user-friendly real-time
interactive way, thus improving efficiency, and patient care.

IQQA® Platform of Real-time Interactive Fully 3D Quantitative Applications

IQQA®-Guide (work-in-progress) further brings the Real-time Interactive Fully Quantitative
technology into the operating room by offering real-time 3D image guidance for abdominal and
thoracic biopsy, interventional procedure and surgery. IQQA-Guide utilizes a 3D map of
individualized anatomic representations extracted from multi-modality image datasets. Through
sophisticated registration algorithms and state-of-the-art electromagnetic tracking, it provides realtime
tracking and referencing to anatomic features of interest in 3D. As a result, physicians are
supported to “see in depth” beyond the anatomy surface during a procedure, and to quantitatively
locate, assess, and adjust the position of instruments relative to the full patient-specific 3D
anatomy of lesion, vessels, organs and segments.

EDDA Technology will also exhibit other IQQA® Family of Products in Booth #7556 at the RSNA
2012, including IQQA®-Liver Function and IQQA-BodyImaging (hosted by the IQQA®-Platform as
works-in-progress), IQQA®-Chest Enterprise CAD (Computer Aided Detection) for assisting
physician’s detection of small lung nodules from digital chest X-ray, and IQQA® –TomoS CAD
(work-in-progress) for Digital X-ray Tomosynthesis. The first prospective study on chest X-ray
CAD published in journal (Academic Radiology Vol. 15:5) demonstrated a significant sensitivity
increase of physician’s nodule detection from 63.8% without IQQA-Chest to 92.7% with IQQAChest
assistance (while specificity kept high at 96.2% from the previous 98.1%).

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in healthcare imaging
and analysis. EDDA offers a series of next generation computer assistance solutions to the entire
patient care management cycle, including enabling early detection and diagnosis of diseases, as
well as enhancing efficiency and precision in treatment planning, management, and follow-up.
EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies
that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is
headquartered in Princeton, New Jersey, and has subsidiaries in Shanghai and Suzhou, China.
IQQA® is a registered trademark of EDDA Technology. www.eddatech.com